What is Apollomics?
Apollomics operates at the intersection of molecular biology and clinical oncology, focusing on the discovery and development of innovative therapies. The company distinguishes itself through a platform designed for combination treatment approaches, targeting specific molecular pathways and immune-related mechanisms. By focusing on difficult-to-treat cancers, Apollomics aims to improve patient outcomes through precision-engineered drug candidates. Its market position is defined by a robust pipeline that leverages deep scientific insights to address the limitations of current standard-of-care treatments, making it a critical player in the next generation of cancer research and development.
How much funding has Apollomics raised?
Apollomics has raised a total of $240.9M across 5 funding rounds:
Angel/Seed
$5M
Series A
$9.8M
Series B
$100M
Series C
$124.2M
Debt
$2M
Angel/Seed (2016): $5M, investors not publicly disclosed
Series A (2016): $9.8M led by OrbiMed Asia
Series B (2019): $100M, investors not publicly disclosed
Series C (2020): $124.2M featuring Ping An Capital
Debt (2026): $2M, investors not publicly disclosed
Key Investors in Apollomics
OrbiMed Asia
OrbiMed Advisors LLC is a premier healthcare-focused investment firm that manages capital across the entire life sciences spectrum, including biopharmaceuticals and medical devices. Their investment strategy emphasizes deep operational expertise and a multi-stage approach to supporting innovation in healthcare.
Ping An Capital
A prominent investment arm focused on strategic growth and capital deployment within the healthcare and technology sectors.
Undisclosed Investor
An institutional participant providing essential backing to support the company's ongoing research and development initiatives.
What's next for Apollomics?
With the recent infusion of capital, Apollomics is poised to transition into a more mature phase of its corporate lifecycle. The strategic focus will likely shift toward accelerating clinical trials, optimizing manufacturing processes for its lead candidates, and potentially exploring new therapeutic indications. As the company scales, it will need to maintain its rigorous scientific standards while navigating the regulatory hurdles inherent in the biotech industry. Investors will be closely monitoring the progression of its molecular pathway targets and the efficacy data emerging from its combination therapy trials, which remain the primary drivers of long-term value creation in this high-stakes sector.
See full Apollomics company page
